Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


LCT files pericyte protective agent provisional patent

LCT files pericyte protective agent provisional patent

7 November 2017 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has filed a provisional patent for pericyte protective agents titled “PERICYTE PROTECTIVE AGENTS FOR NEUROLOGICAL DISORDERS INCLUDING NEURODEGENERATIVE DISEASES, CENTRAL NERVOUS SYSTEM DISEASES AND OTHERS”.

The invention in this provisional patent arises from LCT’s research collaboration with the Centre for Brain Research (CBR) at The University of Auckland. The research collaboration explored how LCT’s products can reverse human brain neurodegenerative processes associated with pericytes (and other brain cells), which help sustain the blood-brain barrier and other homeostatic and haemostatic functions in the brain.

The project had two primary goals. The first was to extend the pipeline for LCT’s lead product NTCELL® by examining the effects of NTCELL on cell cultures derived from human brains with Alzheimer’s disease and Parkinson’s disease. The second was to identify neuroactive constituents of NTCELL and their site of action.

The research was undertaken by Auckland UniServices Limited (UniServices), the commercial research company of The University of Auckland, using the breakthrough drug testing and drug target validation platform, Neurovalida. Neurovalida, developed by Professor Mike Dragunow, Distinguished Professor Sir Richard Faull and Associate Professor Maurice Curtis from the CBR, provides human brain-based neuroscience research collaborations, partnerships and services.

CEO of Living Cell Technologies, Dr Ken Taylor, says he is delighted that the project using CBR’s world class capabilities has resulted in the filing of this provisional patent.

“This will enable LCT to build and extend its expertise on the efficacy of cell therapies which have the potential to treat neurodegenerative disorders. Most important is the ability to generate data from human brain tissue cultures in vitro to lead us to the identification of neuroprotective product candidates.”

Director of the CBR, Distinguished Professor Sir Richard Faull, says he pleased that the project outcome has been so successful.

“The team at the Centre for Brain Research is proud to be part of this collaboration researching disease modifying treatments for Parkinson’s, Alzheimer’s and other neurodegenerative diseases.

“This is a great example of translational neuroscience,” he added.

© Scoop Media

Business Headlines | Sci-Tech Headlines


Bell Gully: Uncertainty Ahead With New Unconscionable Conduct Legislation

new prohibition against ‘unconscionable conduct’ in trade is one of a number of changes to the Fair Trading Act 1986 that come into force from 16 August 2022. The new prohibition may have wide-ranging implications for many businesses... More>>

Statistics: Food Prices Increase 7.4 Percent Annually
Food prices were 7.4 percent higher in July 2022 compared with July 2021, Stats NZ said today... More>>

REINZ: Market Activity And Prices Continue To Ease, First Home Buyers Start To Return To The Market

New Zealand’s winter property market continues its recent trend, slowing from the pace of sales and price rises of last year — properties stay on the market longer and median prices dip... More>>

Kiwi Group Holdings: Fisher Funds Acquires Kiwi Wealth Business

Kiwi Group Holdings Limited (KGHL) today announced the sale of Kiwi Wealth to Fisher Funds for NZ$310 million... More>>

Retail NZ: Welcomes Return Of Cruise Ships

“Cruise visitors were big spenders in retail prior to COVID-19, and retailers in Auckland will be celebrating the arrival of P&O’s Pacific Explorer this morning... More>>

ASB: Full Year Results: Building Resilience Today And For Our Future

In its 175th year, ASB has reported a cash net profit after tax of $1,418 million for the 12 months to 30 June 2022, an increase of $122 million or 9% on the prior year... More>>